Is Eli Lilly and Company (LLY) Stock Halal?
A halal-compliant screen, a transitional profile, and a stronger long-term compounding record.
Eli Lilly and Company (LLY) is currently assessed by purepofo as Halal compliant based on its latest available business activity and financial screening data.
Eli Lilly and Company's growth score of 2.0 out of 4 and maturity score of 2.3 out of 4 still describe a transitional profile rather than a settled one. Product concentration and supply-chain concentration increase dependence on consistent execution.
Move through the brief chapter by chapter, from Halal screening and business direction to return interpretation and the final takeaway.
The Halal assessment provides an initial answer for Eli Lilly and Company; the broader analytical picture depends on quality signals, resilience, return history, and risk.
Eli Lilly and Company (LLY) at a Glance
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Eli Lilly and Company is currently being reviewed as a healthcare company. Its market capitalization sits around 1056.5B USD. The latest EBIT margin is about 45.6%. The indicated dividend yield is roughly 0.6%.
Is Eli Lilly and Company (LLY) Stock Halal?
Eli Lilly and Company is currently assessed as halal compliant. It operates in a Halal-compliant industry. The current one-year outlook signal implies Eli Lilly and Company is expected to remain compliant within the coming year.
On the financial screen, interest income is around 0.98% versus the AAOIFI threshold of 5.00%, debt is around 4.40% versus the AAOIFI threshold of 30.00%, securities is around 2.83% versus the AAOIFI threshold of 30.00%. These thresholds follow AAOIFI-based screening standards used in purepofo’s methodology. The ratio checks currently look healthier than merely passable, which adds confidence to the present status reading.
| Financial ratio | Current level | Threshold |
|---|---|---|
| Interest Income | 0.98% | 5.00% |
| Debt | 4.40% | 30.00% |
| Securities | 2.83% | 30.00% |
Is Eli Lilly and Company (LLY) a High-Quality Business?
The available quality signals are mixed: growth is more developed than maturity, leaving the profile between a growth-oriented and an established operating model. Resilience provides a moderate level of support.
The score mix looks transitional rather than settled, with growth score at about 2.0 out of 4 and maturity score around 2.3 out of 4, placing the current evidence between a growth-oriented and a more established operating profile.
The quality layer is respectable, but still short of the level that would make the stock feel unusually durable. The cleaner support currently comes from Interest Coverage and Liquidity Position, and the resilience score itself sits around 3.0 out of 5.
Valuation Momentum, Profitability Trend, Profit Stability and Dividend Trend help justify the current profile, even if Reinvestment Capacity and Financial Strength still need to improve for the story to look more robust.
How Has Eli Lilly and Company (LLY) Stock Performed?
A good return snapshot should tell investors whether recent gains are broadening, fading, or still lagging behind the longer story. The latest 1-year ROI is +64.1%. The trailing 3-year compounded ROI is +125.0%. The longer 5-year compounded ROI is +435.1%.
The long-run picture is more prominent than the most recent window in the historical record. Returns have come with fairly good risk-adjusted efficiency, which is often what separates a durable performer from a noisy one.
On current consensus-style assumptions, the stock is being framed at about 1328.83 USD versus 1185.68 USD today, leaving a notional +12% across 27 analyst estimates. It is a sentiment snapshot, not a forecast you can bank on.
What Are the Main Risks for Eli Lilly and Company (LLY)?
The risk picture is centered most clearly on product concentration, supply-chain concentration, and ESG controversy exposure.
Why Eli Lilly and Company's Business Lifecycle Matters
Eli Lilly and Company's current lifecycle evidence combines Valuation Momentum, Profitability Trend, Profit Stability and Dividend Trend with constraints around Reinvestment Capacity and Financial Strength. That balance explains the transitional profile and why resilience should be assessed alongside both the stronger and weaker operating signals.
Eli Lilly and Company: Key Takeaways for Halal Investors
From an accessibility-first investor lens, Eli Lilly and Company is currently characterised by a transitional operating profile: growth is more developed than maturity, leaving the operating picture between a growth-oriented and a more established profile, so further evidence of operating durability would strengthen the longer-term quality assessment. Its more supportive signals include a rewarding longer-term return record, valuation momentum and profitability trend.
How to think about stocks
Get occasional insight on how to evaluate stocks, not just what stock to look at next. We write when there is something genuinely useful to add.
By subscribing, you agree to receive this optional email and can withdraw consent later. Read the privacy policy.
Use the investor brief as a starting point, then continue into the broader purepofo research workflow when you want deeper methodology, screening, or comparative context.
If you want a more detailed, institutional-style version of this analysis, you can open the deeper stock review in purepofo advisor, which opens as a separate research experience in a new tab.
Continue with Investor Briefs that share an industry, sector, or business-profile relationship with this company.
This article is provided for informational and educational purposes only. It does not constitute investment, legal, tax, Shariah, or other professional advice, and it is not a recommendation or solicitation to buy, sell, or hold any security. The content is general in nature, is not tailored to your personal circumstances or objectives, and should not be relied on as the sole basis for any investment decision.
Halal assessments, ratings, forecasts, and classifications reflect purepofo's methodology at the time of publication. They may change as company fundamentals, market data, methodology inputs, AAOIFI-based screening interpretations, or other information change. Proprietary scores and forward-looking assessments are inherently uncertain and are not guaranteed to be accurate, complete, or timely.
Third-party data may be used. purepofo does not guarantee the accuracy, completeness, or timeliness of third-party information and is not responsible for errors, omissions, or content provided by others. Logos and trademarks remain the property of their respective owners and are used for identification only.
You should carry out your own research and, where appropriate, consult qualified financial, legal, tax, and Shariah advisers before making any decision. Please also review our Terms and Conditions.
